Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-08-21
2007-08-21
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007200, C424S184100, C424S192100, C424S244100, C530S300000, C530S350000
Reexamination Certificate
active
11066594
ABSTRACT:
The recombinant production of Gap4, a chimeric GapC plasmin binding protein comprising the entire amino acid sequence of theStreptococcus dysgalactiaeGapC protein in addition to unique amino acid sequences from theStreptococcus parauberisandStreptococcus agalactiaeGapC proteins, is described. Also described is the use of Gap4 chimeric GapC protein in vaccine compositions to prevent or treat streptococcal infections in general and mastitis in particular.
REFERENCES:
patent: 4954618 (1990-09-01), Fahnestock
patent: 4977082 (1990-12-01), Boyle et al.
patent: 5108894 (1992-04-01), Bjorck et al.
patent: 5198215 (1993-03-01), De Cueninck
patent: 5237050 (1993-08-01), Boyle et al.
patent: 5328996 (1994-07-01), Boyle et al.
patent: 5721339 (1998-02-01), Boyle et al.
patent: 5753463 (1998-05-01), Briles et al.
patent: 5863543 (1999-01-01), Jiang et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6391316 (2002-05-01), Potter et al.
patent: 2001/0014335 (2001-08-01), Saitoh et al.
patent: 0 887 410 (1998-12-01), None
patent: WO93/14198 (1993-07-01), None
patent: WO96/40928 (1996-12-01), None
patent: WO96/41879 (1996-12-01), None
patent: WO98/18930 (1998-05-01), None
patent: WO99/42588 (1999-08-01), None
patent: WO 00/39299 (2000-07-01), None
Chien et al., “Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection,” Journal of Clinical Microbiology, vol. 37 No. 5, apges 1393-1397 (May 1999).
Baird et al., “Epitopes of Group A Streptococcal M Protein Shared With Antigens of Articular Cartilage and Synovium,”The Journal of Immunology 146(9):3132-3137 (1991).
Bisno, Alan. L., “Group A Streptococcal Infections and Acute Rheumatic Fever,”New Eng J. Med. 325:783-793 (1991).
Bowie et al., “Deciphering the message in protein sequences: tolerances to amino acid substitutions,”Science247:1306-1310, 1990.
Bronze et al., “Epitopes of Streptococcal M Proteins that Evoke Antibodies That Cross-React with Human Brain,”The Journal of Immunology 151(5):2820-2828 (1993).
Cunningham et al., “Study of Heart-Reactive Antibody in Antisera and Hybridoma Culture Fluids Against Group AStrepatococci,” Infection and Immunity 42(2):531-538 (1983).
Dale, J. L., “Multivalent Group A Streptooccal Vaccine Designed to Optimize the Immunogenicity of Six Tandem M Protein Fragments,”Vaccine 17(2):193-200 (1999).
Dale, J. L. and Beachy, G. H., “Multiple, Heart-Cross Reactive Epitopes of Streptococcal M Proteins,”J. Exp. Med. 161:113-122 (1995).
Dale, J. L. and Beach, G. H., “Protective Antigenic Determinant of Streptococcal M Protein Shared With Sarcolemmal Membrane Protein of Human Heart,”J. Exp. Med. 156:1165-1176 (1985).
Finch et al., “Further Studies on the Efficacy of a Live Vaccine Against Mastitis Caused byStreptococcus uberis,” Vaccine 15(10):1138-1143 (1997).
Froude et al., “Cross-Reactivity BetweenStreptococcusand Human Tissue: A Model of Molecular Mimicry and Autoimmunity,”Microbiology and Immunology 145:5-26 (1989).
Gase et al., “Cloning Sequencing and Functional Overexpression of theStreptococcusEquismilis H46A gapC Gene Encoding a Glyceraldehyde-3-Phosphate Dehydrogenase that also Functions as a Plasmin(ogen)-Binding Protein. Purification and Biochemical Characterization of the Protein,”European Journal of Biochemistry 239(1):42-51 (1996).
Hafid et al., “Glyceraldehyde-3-phosphate dehydrogenase from tetrahymena pyriformis: enzyme purification and characterization of a gapC gene with primitive eukayrotic features,”Comparative Biochemistry and Physiology B119:493-503, 1998.
Kehoe, Michael A., “Group A Streptococcal Antigens and Vaccine Potential,”Vaccine 9797:806 (1991).
Lancefield, Rebecca C., “Current Knowledge of Type-Specific M Antigens of Group AStreptococci,” J. of Immunology 89:307-313 (1962).
Langone, John J., “Protein A ofStaphylococcus aureusand Related Immunoglobulin Receptors Produced byStreptococciandPneumonococci,” Advances in Immunology 32:167 (1982).
Liljeqvist et al., “Surface Display of Functional Fibronectin-Binding Domains onStaphylococcus camosus,” FEBS Letters 446:299-304 (1999).
Stolleman, G. H., “RheumatogenicStreptococciand Autoimmunity,”Clin. Immunol. Immunopathology, 61:131-142 (1991).
Fontaine Michael
Perez-Casal Jose
Potter Andrew A.
Campell Bruce R.
Lucas Zachariah
Robins & Pasternak LLP
University of Saskatchewan
LandOfFree
Immunization of dairy cattle with chimeric GapC protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunization of dairy cattle with chimeric GapC protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunization of dairy cattle with chimeric GapC protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857190